This study is a prospective, company-sponsored, non-interventional cohort study of up to 5000 patients in European countries and countries in Middle East who are newly prescribed any available OC. Patients will be followed up approximately 6 months after initial visit. Selection of Study Population: Women can be enrolled after decision for treatment with Yasmin or any other OC has been made. Physicians should consult the full prescribing information for the respective OC before enrolling patients and familiarize themselves with the safety information in the product package label.
Study Type
OBSERVATIONAL
Enrollment
5,446
Patients under regular daily life treatment receiving Yasmin according to local drug information
Patients under regular daily life treatment receiving any other OC according to local drug information
Unnamed facility
Many Locations, Albania
Unnamed facility
Many Locations, Bahrain
Unnamed facility
Many Locations, Egypt
Unnamed facility
Many Locations, Hungary
Unnamed facility
Many Locations, Jordan
Unnamed facility
Many Locations, Kenya
Unnamed facility
Many Locations, Kuwait
Unnamed facility
Many Locations, Lebanon
Unnamed facility
Many Locations, North Macedonia
Unnamed facility
Many Locations, Oman
...and 3 more locations
Analyses of continuation rates and compliance stratified by the subject's knowledge on the respective topics and time spent for counseling.
Time frame: After 3 months and at end of study after approx. 6 months.
Analyses stratified by baseline factors such as age group, presence or absence of cycle disorders, and history of oral contraceptive method will be performed as well.
Time frame: After 3 months and after approx. 6 months.
Special attention will be paid to serious adverse events and unexpected or unlisted ADRs.
Time frame: Over 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.